期刊文献+

Telomerase activity in myelodysplastic syndrome

骨髓增生异常综合征的骨髓细胞端粒酶活性研究(英文)
全文增补中
导出
摘要 To study telomerase activity (TA) and its variation in bone marrow mononuclear cells from patients with myelodysplastic syndrome (MDS) at different stages in comparison with normal bone marrow cells and leukemic cells Methods The TA was semi quantitatively determined in mononuclear cells from 20 normal bone marrow samples, 21 patients with MDS at different stages and 32 cases of acute leukemia by using a polymerase chain reaction enzyme linked immuno sorben assay (PCR ELISA) kit Results The TA in normal bone marrow cells was in the range of 0 to 0 3 units (U) with a mean of 0 11±0 08 U Among them, 3 samples were considered positive in accordance with the standard recommended by the kit’s pamphlet In bone marrow cells from patients with acute leukemia, the TA was ranging from 0 to 0 96 U with a mean value of 0 42±0 26 U The positive rate was 78 1% which was significantly different from that in normal bone marrow (BM) ( P 【0 01) In case of myelodysplastic syndrome, the average level of TA was 0 27±0 19 U (ranging from 0 to 0 97 U) with a positive rate of 66 7% In comparison with normal BM cells, the difference was significant ( P 【0 05) Particularly, the MDS high risk subgroup exhibited a significantly higher activity of telomerase ( P 【0 05) In comparison with INT 1 and INT 2 subgroups in MDS patients based on international prognostic scoring system (IPPS), the difference in TA was also significant ( P 【0 05) The abnormality in cell karyotype was not correlated with TA Conclusion The normal bone marrow cells demonstrate TA at a marginal level while a remarkably increasing level may be seen in acute leukemia patients The BM cells from MDS patients display a moderate TA among which the high risk MDS subgroup with a poor prognostic IPPS score exhibited markedly higher TA 为了研究骨髓增生异常综合征的骨髓单个核细胞中端粒酶的表达特点 ,并与正常骨髓、急性白血病进行比较。方法 我们用PCR ELISA法对 2 0例正常骨髓、2 1例骨髓增生异常综合征 3 2例急性白血病骨髓单个核细胞的端粒酶活性进行半定量检测。结果 发现正常骨髓细胞端粒酶表达范围 0~ 0 3 0U ,平均 0 1 1± 0 0 8U ,其中仅有 3例阳性。急性白血病骨髓细胞端粒酶表达范围 0~ 0 96U ,平均 0 42± 0 2 6U ,阳性率 78 1 % ,与正常骨髓相比 ,有显著性差异 (P <0 0 1 )。MDS端粒酶表达范围 0~ 0 97U ,平均为 0 2 7± 0 1 9U ,阳性率为 66 7%。与正常相比 ,端粒酶表达均值之间的差别有显著性 (P <0 0 5)。其中高风险组端粒酶表达较高 (P <0 0 5)。IPPS评分等级为INT 1 ,2与HIGH组的MDS骨髓细胞端粒酶活性水平之间差异有显著性 (P <0 0 5)。端粒酶活性与染色体异常程度无明显关系。结论 结果提示正常骨髓细胞具有临界水平的端粒酶活性 ,急性白血病端粒酶活性显著升高 ,而MDS则介于正常与急性白血病之间。其中高风险组。
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2002年第10期35-38,145-146,共6页 中华医学杂志(英文版)
基金 ThisstudyhasbeensupportedbythegrantE9705fromtheSuzhouMedicalCollegea thegrantof"333HumanResourceEngineeringFoundation"fromtheJiangsuProvinceGovernment
关键词 telomerase activity · myelodysplastic syndrom e · acute leukemia 端粒酶 骨髓增生异常综合征 急性白血病
  • 相关文献

参考文献8

  • 1TsoplouP,KourakisSymeonidisA,ThanopoulouE ,etal.Apoptosisinpatientswithmyelodysplasticsyndromes:differentialinvolvementofmarrowcellsin"good"versus"poor"prognosispatientsandcorrelationwithapoptosis relatedgenes[].Leukemia.1999
  • 2Legare RD,Gilliland DG.Myelodysplatic syndrome[].Current Opinion in Hematology.1995
  • 3Greenberg P,Christopher C,Michelle M,et al.International scoring system for evaluating prognosis in myelodysplastic syndromes[].Blood.1997
  • 4KimNW,PiatyszekMA,ProwseKR,etal.pecificassociationofhumantelomeraseactivitywithimmortalcellsandcancer[].Science.1994
  • 5Yoshida Y,Stephenson J,Mufti GJ.Myelodysplastic syndromes: from morphology to molecular biology.Part 1.Classification, natural history and cell biology of myelodysplasia[].International Journal of Hematology.1993
  • 6Sawada K,Sato N,Notoya A,et al.Proliferation and differentiation of myelodysplastic CD34+ cells: Phenotype subpopulations of marrow CD34+ cells[].Blood.1995
  • 7Counter C M,Gupta J,Harley C B,et al.Telomerase activity in normal leukocytes and in hematologic malignancies[].Blood.1995
  • 8Rosenfeld C and List A.A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies[].Leukemia.2000

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部